Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 10:00PM GMT
Release Date Price: $77.2 (+1.25%)
Qian Wang
BofA Merrill Lynch, Research Division - Research Analyst

Thank you so much for coming to the Bank of America Healthcare Conference in Vegas. My name is Qian Wang, and I'm on the large cap biotech team here at BAML.

Today, it's my pleasure to have Blueprint to present at our conference. So welcome, Jeff Albers, the CEO of Blueprint. So thank you, and welcome to the podium.

Jeffrey W. Albers
Blueprint Medicines Corporation - CEO, President & Director

Thank you, and on behalf of all the employees at Blueprint Medicines, I want to thank you for including us at the Bank of America conference.

As always, we'll be making forward-looking statements today, and so we refer you to our website or SEC filings and disclaim any obligation to update any of those forward-looking statements.

So today, I'm going to spend the first 10, 15 minutes talking a little bit about Blueprint, who we are and our longer-term vision, and then we'll spend the remainder of the time together focusing in on a couple of our clinical stage programs.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot